Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Operating Activities:
Net loss	$ (2,498,032)	$ (1,332,048)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation	329,919	65,074
Depreciation	505	620
Changes in operating assets and liabilities:
Tax receivable	(72,188)	(35,960)
Prepaid expenses and other current assets	(43,006)	(353,741)
Accounts payable and accrued expenses	190,806	160,925
Accrued interest		308
Net cash used in operating activities	(2,091,996)	(1,494,822)
Financing Activities:
Payments of deferred offering costs	(160,000)
Proceeds from sale of common stock, net of offering costs	103,916	2,913,750
Proceeds from sale of Nexcella common stock	175,000
Net cash provided by financing activities	118,916	2,913,750
Effect of foreign currency on cash	(562)	(2,722)
Net change in cash and cash equivalents	(1,973,642)	1,416,206
Cash and cash equivalents – beginning of period	13,436,714	17,644,478	$ 17,644,478
Cash and cash equivalents – end of period	11,463,072	19,060,684	$ 13,436,714
Supplemental Disclosures of Cash Flow Information:
Interest paid		80
Income taxes paid	5,170	1,622
Supplemental Disclosures of Noncash Financing Information:
Nexcella shares issued for funds previously received	475,000
Accrual of deferred offering costs	11,000
Deferred offering costs charged against proceeds from sale of common stock	$ 2,593